GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...